Bictegravir + Emtricitabine + Tenofovir Alafenamide for HIV

(REINITIATE Trial)

This trial aims to help people living with HIV quickly restart their medication after a break of at least 12 weeks. Researchers are testing a once-daily pill that combines three drugs: bictegravir, emtricitabine, and tenofovir alafenamide, to determine if it can maintain low virus levels and keep people engaged in their care. Participants will also share their reasons for stopping treatment to help improve future support systems. This study is ideal for those diagnosed with HIV who haven't taken any HIV medication for the last 12 weeks and wish to restart treatment. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, and this research seeks to understand how it benefits more patients.

The trial does not specify if you need to stop taking your current medications, but it does mention that you cannot take medications that are not compatible with B/F/TAF. It's best to discuss your current medications with the study team to see if they are allowed.

Research has shown that the combination of bictegravir, emtricitabine, and tenofovir alafenamide is generally safe and well-tolerated. Studies have found this medication combo to be highly effective in controlling HIV. In real-world studies, most individuals taking this treatment achieved and maintained low viral levels in their blood.

The safety profile remains positive, with reports indicating that side effects are usually mild. Common side effects may include headache, tiredness, or nausea, while serious side effects are rare. National guidelines already recommend this combination for treating HIV, supporting its safety and effectiveness.

Researchers are excited about the combination of bictegravir, emtricitabine, and tenofovir alafenamide for treating HIV because it offers a potent, once-daily regimen that simplifies treatment. Unlike other regimens that might require multiple pills or more complex dosing schedules, this combination is co-formulated into a single tablet, making it easier for patients to adhere to their treatment plan. Additionally, bictegravir is a newer integrase inhibitor that has shown strong effectiveness in reducing viral loads with a lower risk of resistance compared to some older treatments. This combination also tends to have a favorable safety profile, potentially minimizing side effects compared to traditional multi-drug therapies.

Research has shown that the combination of bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) effectively treats HIV. In previous studies, 80% to 96% of patients had low levels of HIV in their blood within 24 to 48 weeks, indicating that the virus was controlled to very low levels in most individuals. The treatment is also well-tolerated, with most people not experiencing serious side effects. In this trial, all participants will receive open-label B/F/TAF, with treatment duration determined by baseline viral load. National treatment guidelines widely recommend B/F/TAF, and it has successfully kept HIV under control for extended periods.³⁶⁷⁸⁹